Introduction

Chronic obstructive pulmonary disease (COPD), which is defined as airflow obstruction that is not fully reversible, was ranked fifth among causes of death globally in 2002; however, it is expected to be the third most common cause of death in 2020. The main pathological changes associated with COPD include chronic bronchitis, emphysema and small-airway disease\(^1\). The symptoms of emphysema partially overlap with COPD, and it is one manifestation of a group of chronic, obstructive, and frequently progressive destructive lung diseases\(^2\). Emphysema is characterized by destruction of the alveolar walls and permanent enlargement of the air spaces distal to the terminal bronchioles, which contribute to a reduction in the forced expiratory volume in 1 second (FEV\(_1\))\(^3\). Inflammation, cellular apoptosis, oxidative stress, and protease/antiprotease imbalance are involved in the pathogenesis of emphysema\(^4, 5\). Chemokines and other chemotactic agents, such as interleukin-8 (IL-8), monocyte chemotactic protein-1 (MCP-1), and LTB4, promote the accumulation of inflammatory cells, including macrophages and neutrophils, in the lungs. Lymph follicles containing dendritic cells (DCs) and Th1 cells are present in the parenchyma, which suggests a potential role of the immune response in emphysematous destruction. Also, macrophages and neutrophils can be activated by various insults, such as cigarette smoke, and can subsequently produce reactive oxygen species (ROS) and many inflammatory cytokines, such as tumor necrosis factor (TNF)-\(\alpha\), IL-1\(\beta\), and IL-6. In return, inflammation-activated

Interleukin-17A is involved in development of spontaneous pulmonary emphysema caused by Toll-like receptor 4 mutation

Qing-qing WANG, Hong-zhen YANG, Han-zhi LIU, Su MI, Xiao-wei ZHANG, Hui-min YAN, Yong-gang MA, Xiao-xing WANG, Zhuo-wei HU*

Molecular Immunology and Pharmacology Laboratory, State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

Aim: To explore the pathogenic role of Th17 cells and interleukin-17A (IL-17A)-associated signaling pathways in spontaneous pulmonary emphysema induced by a Toll-like receptor 4 mutant (TLR4\(^{mut}\)).

Methods: Lungs were obtained from wild-type (WT) or TLR4\(^{mut}\) mice that were treated with or without recombinant mouse IL-17A (1 \(\mu\)g kg\(^{-1}\) d\(^{-1}\), ip) from the age of 3 weeks to 3 months. Pulmonary emphysema was determined using histology, immunochemistry, and biochemical analysis. T cell polarization was determined with flow cytometry, the levels of cytokines were measured using ELISA, and the levels of IL-17A-associated signaling molecules were detected using Western blot.

Results: Compared to WT mice, 3 month-old TLR4\(^{mut}\) mice were characterized by significantly reduced infiltration of Th17 cells into lungs (2.49±1.13% vs 5.26±1.39%), and significantly reduced expression levels of IL-17A (3.66±0.99 pg/μg vs 10.67±1.65 pg/μg), IL-23 (12.43±1.28 pg/μg vs 28.71±2.57 pg/μg) and IL-6 (51.82±5.45 pg/μg vs 92.73±10.91 pg/μg) in bronchoalveolar lavage fluid. In addition, p38 MAPK phosphorylation and AP-1 expression were decreased to 27±9% and 51±8%, respectively, of that in WT mice. Treatment of TLR4\(^{mut}\) mice with IL-17A increased the infiltration of Th17 cells into lungs and expression levels of IL-17A, IL-6, and IL-23 in bronchoalveolar lavage fluid, attenuated MDA and apoptosis, and improved emphysema accompanied with increased phosphorylation of p38 MAPK and expression of AP-1.

Conclusion: Th17 cells, in particular the cytokine IL-17A, play a crucial role in the pathogenesis of TLR4\(^{mut}\)-induced spontaneous pulmonary emphysema. Both of them are potential targets for therapeutic strategies for pulmonary emphysema.

Keywords: emphysema; IL-17A; Th17 cells; Toll-like receptor 4
macrophages and neutrophils release proteinases, including elastases and matrix metalloproteinase-9. These proteinases contribute to the degradation of extracellular matrix components and eventually to the development of emphysema. However, anti-inflammatory agents or antioxidants only reduce the symptoms, and they do not affect the decline in FEV1[6]. Thus, further investigation is needed to understand the mechanisms underlying the pathogenesis of emphysema.

There have been many studies that have indicated that Toll-like receptors (TLRs) and TLR-mediated autoimmunity play critical roles in the development and resolution of emphysema[7, 8]. TLRs, as a critical family of pattern recognition receptors, can initiate and orchestrate innate and adaptive immune responses; in addition, they function as sensors of damage-associated molecular pattern and are involved in multiple noninfectious inflammatory diseases, such as acute respiratory distress syndrome, asthma, and COPD. TLR4 and TLR2 play a prominent role in gene-environment interactions that are relevant to COPD-related phenotypes because the interaction between the microbial load and the immune system is a critical determinant of both immune function and asthma/emphysema susceptibility[9]. TLR ligands can activate DCs and subsequently determine the direction of T cell polarization[10]. TLR4 mutation results in pulmonary emphysema through upregulation of NADPH oxidase (Nox) 3 in the lungs and endothelial cells, which enhance oxidant generation and elastolytic activity[7]. Importantly, reduction/oxidation (redox) is a novel factor that has been shown to regulate T cell polarization[11]. Furthermore, the accumulation of ROS is critical for the differentiation of naïve Th cells into Th1 or Th17 cells[12]. A recent study has indicated that IL-17 promotes the growth of airway epithelial cells and that Th17 cells play an important role in inflammation and autoimmune diseases, including emphysema[13].

Therefore, we wondered whether T cell polarization, and in particular differentiation into the Th17 phenotype, was involved in the pathogenesis of TLR4mut-induced spontaneous pulmonary emphysema. We found that TLR4mut-induced spontaneous pulmonary emphysema is associated with reductions in the amount of Th17 cell infiltration into the lungs and in the production of Th17-associated cytokines. Administration of recombinant mouse IL-17A reversed TLR4mut-induced pulmonary emphysema by enhancing the phosphorylation of p38 MAP kinase and the expression of AP-1, suggesting that Th17 cells and IL-17A associated signaling pathways play a crucial role in the pathogenesis of pulmonary emphysema. Furthermore, our results indicate that the IL-17A signaling pathway is a potential target for the development of therapeutics against pulmonary emphysema.

Materials and methods

Materials

In situ cell death detection kits were purchased from Roche Diagnostics Ltd (East Sussex, UK). Malondialdehyde (MDA) assay kits were purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Anti-cleaved caspase 3 was from Cell Signaling (Danvers, MA, USA). ELISA kits for IL-17A, IL-23, IL-6, and TGF-β1 were purchased from eBioscience (San Diego, CA, USA). FITC/PE-conjugated anti-CD4, FITC-conjugated anti-IFN-γ, PE-conjugated anti-IL-13, FITC-conjugated anti-CD4, PE-conjugated anti-CD25, PE-conjugated anti-IL-17A antibodies were purchased from eBioscience. Recombinant mouse IL-17A was purchased from R&D Systems (Minneapolis, MN, USA).

Animals

TLR4mut (C3H/HeJ) mice and corresponding wild-type (WT) mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Mice were maintained under specific pathogen free conditions at the Experimental Animal Center of the Institute of Materia Medica. For therapeutic treatment, TLR4mut mice were randomized into 2 groups and administered recombinant mouse IL-17A (1 μg/kg body weight, ip) or an identical volume of vehicle once every day from 3 weeks of age to the end of the experiment. Mice were sacrificed by injection of excess pentobarbital sodium at 3 months of age. The study protocol was approved by the Institutional Committee for the Ethics of Animal Care and Treatment.

Bronchoalveolar lavage fluid (BALF)

Mice were anesthetized and the lungs were lavaged with 0.6 mL of ice-cold phosphate balance solution (PBS). BALF was centrifuged at 100×g for 15 min at 4 ºC. The supernatant was decanted and stored at -80 ºC for further analysis.

Measurement of lung histology and morphometry

Animals were anesthetized and the lungs were perfused with 4% neutral buffered formalin for 20 min (n=6 in each group) via the tracheal cannula at an airway pressure of 25 cm H2O[14]. The fixed lungs were embedded in paraffin, sectioned, and stained with hematoxylin and eosin (HE) for histological analyses. The average distance between alveolar walls and the mean linear intercept (Lm) were calculated according to established methods[15]. Briefly, Lm was calculated as the total length of each line of the grid passing randomly through the lung and divided by the number of alveolar intercepts. For each pair of lungs, 6 histological fields were evaluated. Lung sections were processed for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay using an in situ cell death detection kit.

Assay of lipid peroxides

MDA was measured using an MDA assay kit from Nanjing Jiancheng Bioengineering Institute according to the manufacturer’s instructions[16].

ELISAs for cytokines in BALF

The concentrations of IL-17A, IL-23, IL-6, and TGF-β1 in BALF were detected using ELISA kits in accordance with the manufacturer’s instructions.
Preparation of single-cell lung suspensions
Single-cell suspensions were prepared from the right lung, as previously described[17]. Briefly, the lung vasculature of anesthetized mice was perfused with PBS until free of blood. The lung was minced; digested with 1 mL digestion medium consisting of RPMI-1640, 1 mg/mL collagenase type 2 (Roche Diagnostics; Indianapolis, IN, USA) and 0.02 mg/mL DNase I (grade II from bovine pancreas) for 60 min at 37 °C; subjected to red blood cell lysis (eBioscience); passed through a 100 μm cell strainer; and kept on ice until labeling.

Flow cytometry
The Th1/Th2 mouse T cell subpopulations in single-cell lung suspensions were labeled with FITC-conjugated anti-CD4, PE-conjugated anti-IFN-γ, and Alexa 647-conjugated anti-IL-13 antibodies. Th1 and Th2 cells were defined as CD4+ IFN-γ+ cells and CD4+ IL-13+ cells, respectively. Similarly, regulatory T cells (Tregs) were labeled with FITC-conjugated anti-CD4 and PE-conjugated anti-CD25 antibodies and were defined as CD4+ CD25+ cells; Th17 cells were labeled with FITC-conjugated anti-CD4 and PE-conjugated anti-IL17 antibodies and were defined as CD4+ IL-17+ cells.

Surface molecule expression of single-cell lung suspensions was analyzed using multicolor flow cytometry, as previously described[18]. Briefly, single-cell lung suspensions were suspended in cold PBS containing 3% FBS and 0.02% NaN3. The cells were then incubated with a mixture of rat and mouse IgG (1:1) to reduce nonspecific binding, followed by serial incubations with saturating concentrations of FITC-conjugated mAb and/or PE-conjugated mAb for 1 h at 4 °C. Isotype-matched mAbs were used in control samples. After incubation, 20,000 stained cells were analyzed using CellQuest software (BD Biosciences, Sparks, MD, USA). In addition, the levels of various cytokines, such as IFN-γ, IL-13, and IL-17, were determined by cytokine arrays, as previously described[19]. Cytokine detection was based on the measurement of the fluorescent intensity of the captured cytokine and its specific detection antibodies. The fluorescence data were collected and analyzed as described above.

Western blot analysis
Cytoplasmic and nuclear proteins were extracted from mouse lungs, and Western blots were performed as previously described[20]. Briefly, protein extracts were resolved on 10% SDS-PAGE. Immunoblot analysis was performed with enhanced chemiluminescence reagents (Amersham Pharmacia Biotech, Chicago, IL, USA).

Statistical analyses
Data were expressed as means±SD. Statistical analyses were performed with SPSS 13.0 using paired-samples t-tests or non-parametric tests. For the therapeutic study, one-way ANOVA analysis was performed to assess data differences among various groups. Differences were considered significant at a level of P<0.05.

Results
TLR4 mutation enhances apoptosis and oxidative stress in the lungs
Different strains of TLR4-mutant mice (C3H/HeJ, C57BL/10ScNJ, and C57BL/6J backgrounds) all have been shown to exhibit increased lung volumes at 3 months of age, which indicates that the observed phenotypes were independent of strain[7]. In this study, C3H/HeJ TLR44mut mice were used to investigate the mechanisms underlying the development of TLR44mut-induced spontaneous emphysema. The lungs of TLR44mut mice showed destruction of the alveolar architecture and enlargement of the air spaces at 3 months of age but not at 0.5 or 1 month of age (Figure 1A). Also, the morphometric quantitation of airspace enlargement revealed that Lm was larger in TLR44mut mice than in WT mice at 3 months of age (66.12±6.61 μm vs 55.81±3.93 μm, P<0.05), but there were no differences between the lungs of WT and those of TLR44mut mice at either 0.5 or 1 month of age (Figure 1B). In addition, compared with WT mice, TLR4 mutation increased the number of TUNEL− (blue-green) cells and the levels of MDA in the lungs at 3 months of age (5.09±1.11% vs 1.92±1.01%, P<0.01, and 0.74±0.11 nmol·mg−1 protein vs 0.47±0.15 nmol·mg−1 protein, P<0.01, respectively) (Figures 1C and 1E). Also, the expression of cleaved caspase 3, which contributes to cellular apoptosis, was enhanced in the lungs of TLR44mut mice (Figure 1D). These results indicate that TLR4 mutation causes pulmonary emphysema in mice at 3 months of age, which is consistent with the report from Zhang et al[7]. Therefore, three-month-old TLR44mut mice were used as our model of spontaneous emphysema for further studies.

Th2, Th17, and Th17-associated cytokines are attenuated in the lungs of TLR44mut mice
TLR activation regulates the maturity of DCs, which prime naïve T cells to determine their polarization into Th1, Th2, Treg or Th17 cells[21]. Th1 cells primarily secrete IL-1, IL-2, IL-12, IL-15, IFN-γ, and TNF-α; T2 cells mainly secrete IL-4, IL-5, IL-6, IL-13; Treg cells principally secrete IL-10 and TGF-β; and Th17 cells predominantly secrete IL-17, IL-6, TNF-α, and IL-22[10]. TLR4 mutation has been shown to reduce the activity of antioxidants and enhance the activity of Nox3 and the production of ROS[7], which contribute to T cell polarization by changing the redox status[21]; our results indicate that the numbers of CD4+IL-17 Th17 cells and CD4+IL-13+ Th2 cells were decreased in the lungs of 3-month-old TLR44mut mice (2.49±1.13% vs 5.26±1.39%, P<0.01, and 6.25±4.62% vs 13.1±4.07%, P<0.05, respectively; Figures 2A and 2C). However, TLR4 mutation did not change the number of CD4+CD25+ Treg cells or CD4+IFN-γ+ Th1 cells (Figures 2B, 2D).

The development and differentiation of Th17 cells are regulated by many cytokines, such as IL-6, transforming growth factor (TGF)-β1, IL-23, IL-21, and IL-1. In particular, syner-
gistic activation of TGF-β1 and IL-6 can effectively induce the differentiation of naïve CD4+ T cells into highly pathogenic Th17 cells, while IL-23 is considered to play a vital role in the generation of Th17 cells, which can mediate the immune response[22]. Compared with WT mice, TLR4mut mice contained lower levels of IL-17A (Figure 2E), IL-23 (Figure 2F), and IL-6 (Figure 2H) in the BALF at 3 months of age (3.66±0.99 pg/μg vs 10.67±1.65 pg/μg, 12.43±1.28 pg/μg vs 28.71±2.57 pg/μg, and 51.82±5.45 pg/μg vs 28.71±2.57 pg/μg, respectively, P<0.01), while they displayed higher levels of TGF-β1 (168.18±9.09 pg/μg vs 102.27±6.82 pg/μg, P<0.05; Figure 2G). These results indicate that the infiltration of Th17 cells and the production of Th17-associated cytokines were attenuated in TLR4mut mice at 3 months of age.

TLR4 mutation reduces phosphorylation of p38 MAPK and the expression of AP-1

TLR4mut mice have been shown to be characterized by reduced antioxidant activity and enhanced Nox3 expression and ROS production[7]. Oxidative stress plays a fundamental role in the induction of inflammation through the upregulation of redox-sensitive protein kinases and transcription factors, such as MAPK, AP-1, and NF-κB, which are also the downstream signaling molecules of IL-17A[23]. Thus, we examined the changes in the levels of these signaling molecules in the lungs of 3-month-old TLR4mut mice. Compared with WT mice, TLR4 mutation inhibited the phosphorylation of p38 MAPK in the lungs (0.27±0.09 fold of WT levels, P<0.01; Figure 3A) but did not affect the phosphorylation of ERK and JNK kinases in the lungs (Figures 3B and 3C). In addition, TLR4 mutation decreased the expression of AP-1 in the lungs (0.51±0.08 fold of WT levels, P<0.05; Figure 3D) but did not affect the phosphorylation of IkB and NF-κB in the lungs (Figures 3E and 3F). These results indicate that TLR4 mutation results in a reduction in p38 MAPK phosphorylation and AP-1 expression.

IL-17A administration ameliorates TLR4mut-induced pulmonary emphysema

To restore the effects caused by Th17 cells, TLR4mut mice were administered mouse IL-17A. As expected, IL-17A reduced the TLR4mut-induced destruction of the normal alveolar architecture and enlargement of the air spaces distal to the...
terminal bronchioles, and it also decreased Lm (Figures 4A, 4C), TUNEL+ apoptotic cells (Figures 4B, 4D) and the levels of MDA (Figure 4E) in the lungs. To evaluate the effectiveness of IL-17A treatment, we examined the infiltration of Th2 cells and Th17 cells into the lungs and the levels of IL-17A, IL-23, IL-6, and TGF-β1 in the BALF of TLR4mut mice. IL-17A administration enhanced the production of IL-17A (Figure 5A), IL-23 (Figure 5B), and IL-6 (Figure 5C) (14.58±1.31 pg/μg vs 3.56±1.50 pg/μg, P<0.001; 25.30±8.22 pg/μg vs 16.33±5.58 pg/μg, P<0.05; and 129.6±10.87 pg/μg vs 57.6±3.66 pg/μg, P<0.01, respectively) but did not enhance the levels of TGF-β1 (Figure 5D). Additionally, IL-17A treatment increased
Th17 cell infiltration (5.77%±2.91% vs 2.49%±1.13%, P<0.05; Figure 5E), but it did not significantly enhance Th2 cell infiltration (Figure 5F). Furthermore, IL-17A treatment reversed TLR4mut-reduced phosphorylation of p38 MAPK (Figure 5G) and expression of AP-1 (Figure 5H) in the lungs of 3-month-old TLR4mut mice (1.06±0.08 fold higher than WT vs 0.27±0.09 fold of WT levels, P<0.01 and 2.34±0.24 fold higher than WT vs 0.51±0.08 fold of WT levels. P<0.01, respectively). These results indicate that treatment of TLR4mut mice with IL-17A ameliorates pulmonary emphysema though restoration of Th17 cell infiltration and enhancement of IL-17-associated signaling.

Discussion

In this study, we observed that TLR4 mutation results in age-dependent development of spontaneous pulmonary emphysema in 3-month-old mice, which is consistent with the report by Zhang et al [7]. The progression of emphysema in TLR4-mutant mice is akin to the progression of emphysema that develops in humans. Therefore, spontaneous emphysema in TLR4-mutant mice is an excellent model for investigating the pathogenesis of emphysema. Emphysema is considered an autoimmune disease [8], while IL-17 has been demonstrated to play vital roles in autoimmune diseases as a major proinflammatory mediator that promotes the production of many chemokines, cytokines, and growth factors [31]. Thus, it is important to provide evidence to establish whether there is a relationship between Th17 cells or IL-17 cytokines and TLR4mut-induced emphysema. Our studies demonstrate that infiltration of Th17 cells and expression of IL-17 are attenuated in the lungs of 3-month-old TLR4mut mice with emphysema, and the p38 MAPK and AP-1 pathways are inhibited in the lung tissue of TLR4mut mice with emphysema. Moreover, administration of recombinant mouse IL-17A resulted in restored Th17 cell infiltration and enhanced IL-17A, IL-23, and IL-6 expression, which reversed the attenuated phosphorylation of p38 MAPK and expression of AP-1, decreased the levels of MDA, inhibited cellular apoptosis, and reversed TLR4mut-induced pulmonary emphysema. However, although the infiltration of Th2 cells was attenuated in the lungs of 3-month-old TLR4mut mice with emphysema, administration of recombinant mouse IL-17A did not raise the levels of infiltrating Th2 cells into the lungs. Our findings indicate that Th17 cells, and in particular the cytokine IL-17A secreted from these cells, play a crucial role in lung epithelia integration during animal development, suggesting that Th17 cells and IL-17A-associated signaling pathways are potential targets for novel pulmonary emphysema therapies.

The mechanism governing the enhanced expression of IL-17A and Th17-associated cytokines after administration of IL-17A is associated with an increase in lung-infiltrating Th17 cells. TGF-β1 and IL-6 have been shown to be required for the differentiation of naïve T cells into Th17 cells in mice [22], while IL-23 has been shown to stabilize and expand the population of Th17 cells [33]. In TLR4mut mice, the expression levels of IL-17, IL-6 and IL-23 in the lungs are all depressed, which results in an attenuation of the lung-infiltrating Th17 cells. A previous study indicated that IL-17 is an important inducer of IL-6.
expression\textsuperscript{[20]}; our recent work showed that IL-17A directly induces the expression of TGF-β1 (Mi \textit{et al}, unpublished observations). In our current study, we found that administration of IL-17A recovers the expression of IL-6 and IL-23 in the lungs of TLR4\textsuperscript{mut} mice. Indeed, Mudter \textit{et al} found that over-expression of IRF4 using retroviral infection induces IL-17 production and that IL-17 together with IL-6 induces RORγt expression, thereby controlling Th17-dependent colitis\textsuperscript{[27]}. Our findings have been supported by other studies as well. Inoue \textit{et al} have reported that IL-17A can stimulate keratinocytes to produce vascular endothelial growth factor (VEGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-α, IL-8, and CXCL10 and subsequently promote the growth and repair of airway epithelial cells\textsuperscript{[13]}. Additionally, up-regulation of IL-17A has been demonstrated to induce the process of tissue fibrosis, which is opposite to the process of emphysema, in chronic periodontitis sites, heart, skin and lungs\textsuperscript{[28, 29]}. However, there have also been some reports that are opposed to the above-mentioned results regarding the association between IL-17A and emphysema. Others have indicated that airway infiltration of CD4\textsuperscript{+}CCR6\textsuperscript{+} Th17 cells are associated with chronic cigarette smoke induced airspace enlargement\textsuperscript{[30, 31]}. Four-month exposure to smoke, a major stimulator of emphysema, can induce significant increases in IL-17 levels in the pulmonary airway\textsuperscript{[32]}. These studies indicate that the physiological concentration of IL-17A is a critical factor for lung epithelial development and for tissue repair or regeneration after tissue injury. However, excessive

Figure 4. Treatment of TLR4\textsuperscript{mut} mice with IL-17A ameliorated spontaneous pulmonary emphysema. (A) IL-17A ameliorated alveolar enlargement and Lm of lung tissue in TLR4\textsuperscript{mut} mice. Left panel, the alveolar enlargement was detected with histological analysis lung sections by HE staining (n=6). Original magnification, ×100. Scale bar, 100 μm. (B) Treatment with IL-17A decreased the TUNEL\textsuperscript{*} apoptotic cells in the lungs. The panel showed the representative merged images of lung sections stained with TUNEL (green) and DAPI staining (blue). Arrows indicate representative TUNEL\textsuperscript{*} (blue-green) cells. Original magnification, ×200. (C) The summary of Lm. (D) The summary for the number of TUNEL\textsuperscript{*} cells in lungs. (E) IL-17A treatment reduced the levels of MDA in the lungs from 3-month-old TLR4\textsuperscript{mut} mice (n=6). Data are means±SD (n=6). \textsuperscript{b}P<0.05, \textsuperscript{c}P<0.01 vs WT mice; \textsuperscript{d}P<0.05, \textsuperscript{e}P<0.01 vs TLR4\textsuperscript{mut} mice.
expression levels of IL-17A (plus other inflammatory factors, such as TGF-β1) can result in tissue fibrosis and even organ dysfunction.

The attenuation of Th17 cells and IL-17A-associated factors is mainly due to a mutation in TLR4 signaling. Indeed, there are a number of studies that have indicated a regulatory role for TLR4 activation in the development of Th17 cells and the production of Th17-associated cytokines. Under physiological conditions, basal activity of TLR4 induced by damage-associated molecular pattern molecules, such as myeloid-related...
protein-8 (Mrp8) and Mrp14, is required for Th17-induced protective immunity that contributes to the defense against infection and the repair of slight tissue injury[35, 34]. Under infectious conditions, pathogens induce a higher level of Th17-associated factors, such as IL-17, IL-1β, pSTAT3, and RORγt, through activation of TLR4[35]. Indeed, TLR4 activity has been shown to be required for gram-negative bacterial pneumonia-induced IL-17 production[36] and for the mycobacterium tuberculosis-induced IL-17A response[37]. TLR4-mutant mice display lower expression levels of IL-1β, TNF-α, IFN-γ, IL-17, and IL-23 in the lungs after vaccination with pertussis vaccines[38]. Interestingly, TLR2-promoted Th2/Th17 responses are caused by activation of TLR4 and TLR7/8 and subsequent abrogation of the type I IFN amplification loop[39]. However, further investigations are needed to fully understand the mechanisms concerning how TLR4 activity regulates the development of Th17 cells and the production of Th17-associated factors.

In summary, our current study indicates that Th17 cells and IL-17A-associated signaling molecules play a crucial role in TLR4<sup>mut</sup>-induced spontaneous pulmonary emphysema. Importantly, treatment of TLR4-mutant mice with exogenous IL-17A enhanced the phosphorylation of p38 MAP kinase and the expression of AP-1 and subsequently decreased apoptosis levels and reversed TLR4<sup>mut</sup>-induced pulmonary emphysema. Our study highlights the fact that Th17 cells and IL-17A-associated signaling molecules are potential targets for the development of therapeutic strategies against pulmonary emphysema.

Acknowledgements
This study was supported by grants from the National Major Basic Research Program of China (2006CB503808), the Creation of Major New Drugs (2009ZX09301-003-13), and the National Natural Science Foundation of China (30672468; 30901814; 81030056). Dr Zhuo-wei HU is also supported by the Cheung-Kong Scholars Programme from the Ministry of Education and the Senior Oversea Chinese Scholar Fund from the Ministry of Personnel of People’s Republic of China.

Author contribution
Qing-qing WANG performed research experiments, analyzed data and wrote the manuscript; Hong-zhen YANG performed part of the research experiments and helped write the manuscript; Han-zhi LIU, Su MI, Xiao-wei ZHANG, Hui-min YAN, Yong-gang MA, and Xiao-xing WANG performed part of the research experiments together with Qing-qing WANG; and Zhuo-wei HU conceived and designed the experiments, edited and modified the manuscript.

References
1 Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007; 87: 1047–82.
2 Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest 2008; 118: 394–402.
3 Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217–27.
4 Boutilier A, Goven D, Boczkowski J, Bonay M. Oxidative stress targets in pulmonary emphysema: focus on the Nrf2 pathway. Expert Opin Ther Targets 2010; 14: 329–46.
5 Horowitz JC, Martinez FJ, Thannickal VJ. Mesenchymal cell fate and phenotypes in the pathogenesis of emphysema. COPD 2009; 6: 201–10.
6 Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet 2007; 370: 774–85.
7 Zhang X, Shan P, Jiang G, Cohn L, Lee PJ. Toll-like receptor 4 deficiency causes pulmonary emphysema. J Clin Invest 2006; 116: 3050–9.
8 Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567–9.
9 Vercelli D. Gene-environment interactions in asthma and allergy: the end of the beginning? Curr Opin Allergy Clin Immunol 2010; 10: 145–8.
10 Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32–46.
11 Gill R, Tsang A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010; 48: 1121–32.
12 Won HY, Sohn JH, Min HJ, Lee K, Woo HA, Ho YS, et al. Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing Th2 and Th17 cell development. Antioxid Redox Signal 2010; 13: 575–87.
13 Inoue D, Numasaki M, Watanabe M, Kubo H, Sasaki T, Yasuda H, et al. IL-17A promotes the growth of airway epithelial cells through ERK-dependent signaling pathway. Biochem Biophys Res Commun 2006; 347: 852–8.
14 Kawakami M, Matsuo Y, Yoshiura K, Nagase T, Yamashita N. Sequential and quantitative analysis of a murine model of elastase–induced emphysema. Biol Pharm Bull 2008; 31: 1434–8.
15 D’Hulst AI, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J 2005; 26: 204–13.
16 Zha RP, Xu W, Wang WY, Dong L, Wang YP. Prevention of lipopolysaccharide-induced injury by 3,5-dicaffeoylquinic acid in endothelial cells. Acta Pharmacol Sin 2007; 28: 1143–8.
17 Traidl-Hoffmann C, Mariani V, Hochrein H, Karg K, Wagner H, Ring J, et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005; 201: 627–36.
18 Yang HZ, Cui B, Liu HZ, Chen ZR, Yan HM, Hua F, et al. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol 2009; 182: 692–702.
19 Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042–9.
20 Cai WF, Zhang XW, Yan JH, Ma YG, Wang XX, Yan J, et al. Pollen-associated phytoprostanes inhibit dendritic cell immunostimulatory DNA. J Immunol 1998; 161: 3042–9.
21 Amati L, Pepe M, Passeri ME, Mastronardi ML, Jirillo E, Covelli V. Toll-like receptor signaling mechanisms involved in dendritic cell activation: potential therapeutic control of T cell polarization. Curr Pharm Des 2006; 12: 4247–54.
22 Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu
23 Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556–67.
24 Hong SC, Lee SH. Role of Th17 cell and autoimmunity in chronic obstructive pulmonary disease. Immune Netw 2010; 10: 109–14.
25 McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23 — IL-17 immune pathway. Trends Immunol 2006; 27: 17–23.
26 Kishimoto T. Interleukin-6: from basic science to medicine — 40 years in immunology. Annu Rev Immunol 2005; 23: 1–21.
27 Mudter J, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, et al. IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo. Inflamm Bowel Dis 2011; 17: 1343–58.
28 Duarte PM, Santos VR, Dos Santos FA, de Lima Pereira SA, Rodrigues DB, Napimoga MH. Role of smoking and type 2 diabetes in the immunobalance of advanced chronic periodontitis. J Periodontol 2011; 82: 429–38.
29 Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502–15.
30 Harrison OJ, Foley J, Bolognese BJ, Long E 3rd, Podolin PL, Walsh PT. Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargement. Immunol Lett 2008; 121: 13–21.
31 Lane N, Robins RA, Corne J, Fairclough L. Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clin Sci (Lond) 2010; 119: 75–86.
32 Melgert BN, Timens W, Kerstjens HA, Geerlings M, Luinge MA, Schouten JP, et al. Effects of 4 months of smoking in mice with ovalbumin-induced airway inflammation. Clin Exp Allergy 2007; 37: 1798–808.
33 Tang H, Pang S, Wang M, Xiao X, Rong Y, Wang H, et al. TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice. J Immunol 2010; 185: 2563–9.
34 Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010; 16: 713–7.
35 Mu HH, Hasebe A, Van Schelt A, Cole BC. Novel interactions of a microbial superantigen with TLR2 and TLR4 differentially regulate IL-17 and Th17-associated cytokines. Cell Microbiol 2011; 13: 374–87.
36 Bhan U, Ballinger MN, Zeng X, Newstead MJ, Cornicelli MD, Standiford TJ. Cooperative interactions between TLR4 and TLR9 regulate interleukin 23 and 17 production in a murine model of gram negative bacterial pneumonia. PLoS One 2010; 5: e9896.
37 van de Veerdonk FL, Teirlinck AC, Kleinnijenhuis J, Kullberg BJ, van Crevel R, van der Meer JW, et al. Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. J Leukoc Biol 2010; 88: 227–32.
38 Banus S, Stenger RM, Gremmer ER, Dormans JA, Mooi FR, Kimman TG, et al. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol 2008; 9: 21.
39 Wenink MH, Santegoets KC, Broen JC, van Bon L, Abdollahi–Roodsaz S, Popa C, et al. TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop. J Immunol 2009; 183: 6960–70.